BioTools Innovator selects CellChorus as a top life sciences company

CellChorus joins the 2022 BioTools Innovator Accelerator, which features best-in-class life science startups from around the world

PRESS RELEASE

HOUSTON, Texas — July 6, 2022 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced that it has been selected for the 2022 BioTools Innovator Accelerator. BioTools Innovator is the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health.

Applicants to BioTools Innovator Accelerator included more than 160 companies from 23 countries. A select group were invited to pitch and be evaluated by representatives from companies including Agilent, Alira Health, Biomedical Advanced Research and Development Authority (BARDA), Danaher, Draper, Eppendorf, General Inception, Hackensack Meridian Health, Illumina Ventures, InDevR, Johnson & Johnson Innovation, MilliporeSigma, Mira Life Science Ventures, Northpond Ventures, Thermo Fisher Scientific, Tosoh USA, Teknova, and VC23.

"These 14 companies represent the next frontier of innovative technologies that will help us develop solutions to diagnose and treat diseases more effectively and live healthier," said Kathryn Zavala, Managing Director of BioTools Innovator. Five of the companies will be selected to compete in the final competition taking place during the BioTools Innovator Capstone Event on October 13, 2022 immediately following the conclusion of the Cell & Gene Meeting on the Mesa at the Park Hyatt Aviara Resort in Carlsbad, California.

About CellChorus

CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based artificial intelligence (AI) to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.

Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com

SOURCE CellChorus Inc.